Needham Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $86

Benzinga Newsdesk www.benzinga.com Negative 57.5%

Neg 57.5% Neu 0% Pos 0%

Needham analyst Joseph Stringer maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and lowers the price target from $105 to $86.